Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00355901 · ClinicalTrials.gov registry record
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
A clinical trial, sponsored by PDL BioPharma.
- Terminated
- Registry status
- 300
- Enrollment target
NCT00355901 is a clinical trial that was terminated before completion, run by PDL BioPharma. The registered enrollment target is 300 participants.
The verdict
NCT00355901 was terminated before completion, sponsored by PDL BioPharma.
- TERMINATED
- Registry status
- 300 participants
- Enrollment target
Study Summary
To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
Interventions
- DRUG Visilizumab (Nuvion®; HuM291)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2006-09 |
| Est. Completion | 2012-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00355901
The ClinicalTrials.gov registry entry for NCT00355901 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PDL BioPharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Visilizumab (Nuvion®; HuM291) is the first listed.
NCT00355901 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00355901 about?
NCT00355901 is a clinical study titled "An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis". To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
What is the current status of trial NCT00355901?
This trial is currently terminated. The enrollment target is 300 participants. The study started on 2006-09. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00355901?
The interventions under investigation include: Visilizumab (Nuvion®; HuM291) (DRUG).
Who is sponsoring clinical trial NCT00355901?
This trial is sponsored by PDL BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.